![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed, Inc. Selects inVentiv Health to Provide Sales Team for Gralise(TM)
June 20, 2011 07:00 ET
|
Depomed, Inc.
BURLINGTON, Mass. and MENLO PARK, Calif., June 20, 2011 (GLOBE NEWSWIRE) -- inVentiv Health, offering best-in-class clinical, consulting and commercial services to the healthcare industry, and...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
New Analyses of Safety and Efficacy Data of Depomed's Gralise(TM) to be Presented at the 63rd Annual Meeting of the American Academy of Neurology
April 12, 2011 17:26 ET
|
Depomed, Inc.
MENLO PARK, Calif., April 12, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that two new analyses of phase 3 clinical data of Gralise™ (gabapentin), a once-daily evening...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Reports Fourth Quarter and Year-End 2010 Financial Results
March 03, 2011 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the fourth quarter and year ended December 31, 2010.
"We are pleased to report...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Completes Enrollment of Breeze 3 Phase 3 Clinical Trial for Non-Hormonal Treatment in Menopausal Hot Flashes
March 03, 2011 04:00 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it has completed enrollment of Breeze 3, the company's pivotal Phase 3 clinical trial evaluating...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Announces US Food and Drug Administration Approval of GRALISE(TM) (gabapentin) Once-Daily Tablets for Treatment of Post-Herpetic Neuralgia
January 28, 2011 19:30 ET
|
Depomed, Inc.
MENLO PARK, Calif., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that US FDA has approved GRALISE™ (gabapentin) Tablets for once-daily treatment of post-herpetic...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Will Engage in Mediation to Resolve Dispute With Abbott; Comments on DM-1796 Regulatory Status and Orphan Drug Designation
January 18, 2011 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it will engage in a mediation process with Abbott Products, Inc., regarding Abbott's...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed to Present at the UBS Global Life Sciences Conference and the Fifth Annual JMP Securities Healthcare Conference
September 17, 2010 17:59 ET
|
Depomed, Inc.
MENLO PARK, Calif., Sept. 17, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the UBS Global...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
September 09, 2010 07:00 ET
|
Depomed, Inc.
MENLO PARK, Calif., Sept. 9, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the Rodman &...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Reaches SPA Agreement With FDA for Phase 3 Hot Flash Trial
August 11, 2010 07:00 ET
|
Depomed, Inc.
MENLO PARK, Calif., Aug. 11, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special...
![Depomed, Inc. Logo](/news-release/logo/219014/0/219014.jpg?lastModified=12%2F10%2F2016%2000%3A23%3A44&size=2)
Depomed Licenses GLUMETZA(R) Data and Acuform(R) Technology
August 05, 2010 16:40 ET
|
Depomed, Inc.
MENLO PARK, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceutica N.V. has licensed worldwide rights to Depomed's Acuform® gastric...